Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
13.72
-0.47 (-3.31%)
Official Closing Price
Updated: 4:10 PM EDT, May 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
September 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
September 24, 2021
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in...
Via
Benzinga
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
September 22, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
September 21, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
September 21, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...
Via
Benzinga
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
September 16, 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for...
Via
Benzinga
Exposures
Product Safety
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 15, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Pressure Day
September 13, 2021
Today a recovery came to markets with a particular impact on uranium shares.
Via
Talk Markets
ADHD Drug Developer Cingulate Plans NASDAQ Debut
September 10, 2021
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Why Novavax Stock Is Slipping Again Today
September 10, 2021
A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock.
Via
The Motley Fool
Exposures
COVID-19
Why Novavax Stock Surged Today
September 07, 2021
The biotech's coronavirus-related revenue could be about to soar.
Via
The Motley Fool
Exposures
COVID-19
NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today
September 07, 2021
A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly.
Via
InvestorPlace
Exposures
COVID-19
Novavax Shares Surge On Vaccine Supply Deal With Japan
September 07, 2021
Novavax, Inc. shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal.
Via
Talk Markets
Exposures
COVID-19
Novavax Shares Surge On Vaccine Supply Deal With Japan
September 07, 2021
Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda...
Via
Benzinga
Exposures
COVID-19
Mu - The Newest Worry
September 03, 2021
Today London and New York fell on the huge drop in new employment levels in August.
Via
Talk Markets
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
September 02, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did...
Via
Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...
Via
Benzinga
Exposures
COVID-19
Product Safety
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
September 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna Reviews Contamination In Vaccine Lot Distributed In Japan
September 01, 2021
Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of...
Via
Benzinga
Exposures
COVID-19
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
August 30, 2021
New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)...
Via
Benzinga
Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know
August 30, 2021
After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19...
Via
Benzinga
Topics
Death
Exposures
COVID-19
Death
Suspected Metallic Particles Behind Moderna's Japan COVID-19 Jab Contamination: Reuters
August 27, 2021
Metallic particle is believed to be a contaminant found in a batch of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines delivered to Japan, Japanese public broadcaster...
Via
Benzinga
Exposures
COVID-19
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
August 26, 2021
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...
Via
Benzinga
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns
August 26, 2021
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia...
Via
Benzinga
Exposures
COVID-19
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
August 18, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Friday the Thirteenth
August 13, 2021
The stock week in points eastward was mixed. The USA markets face a bear correction.
Via
Talk Markets
Takeda To Lead Finch-Partnered Microbiome IBD Drug
August 10, 2021
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE: TAK) has elected to take the lead on the development of FIN...
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.